During the past decade, Our Dear Lady Hospital, Aalst Campus conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Our Dear Lady Hospital, Aalst Campus" are "HER2+ Metastatic Breast Cancer (MBC)" (1 trials), "Non Small Cell Lung Cancer Metastatic" (1 trials) and "Platinum Resistant Ovarian Cancer" (1 trials). Many other conditions were trialed in "Our Dear Lady Hospital, Aalst Campus" in a lesser frequency.

Most popular intervention types in "Our Dear Lady Hospital, Aalst Campus" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "capecitabine" (1 trials), "lapatinib" (1 trials), "neratinib" (1 trials) and "upifitamab rilsodotin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Our Dear Lady Hospital, Aalst Campus" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Our Dear Lady Hospital, Aalst Campus". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Our Dear Lady Hospital, Aalst Campus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Our Dear Lady Hospital, Aalst Campus, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".